(6-methylsulfanyl-pyrazin-2-yl)-phenyl-amine | 642459-13-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (6-methylsulfanyl-pyrazin-2-yl)-phenyl-amine
• 英文别名: 6-methylsulfanyl-N-phenylpyrazin-2-amine
• CAS: 642459-13-0
• 化学式: C₁₁H₁₁N₃S
• 分子量: 217.294
• InChiKey: CHDBRNBYJAIHQV-UHFFFAOYSA-N

物化性质

• 沸点：
  364.3±42.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-氯-N-苯基吡嗪-2-胺 、 2,2,2-三氟乙醇 在 sodium hydride 、 二甲基亚砜 作用下， 以 二甲基亚砜 为溶剂， 反应 72.25h， 以49%的产率得到phenyl-[6-(2,2,2-trifluoroethoxy)-pyrazin-2-yl]-amine
  参考文献：
  名称：

  [EN] 2-AMINOPYRAZINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  [FR] COMPOSES PHARMACEUTIQUES

  摘要：

  公开号：

  WO2004004730A3

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2004004730A2

  公开（公告）日：2004-01-15

  The invention provides a compound of the general formula (I) wherein R1 is selected from hydrogen, cycloalkyl and cycloalkenyl having 3 to 7 ring members; phenyl-C1-4 alkyl or a group R4-A-CH2-, R2 is selected from aryl and heteroaryl having five to twelve ring members; cycloalkyl and cycloalkenyl having 3 to 7 ring members; a group (CR6R7)pE-R8, or R1 and R2 together with the nitrogen atom to which they are attached form a heterocyclic group having 5 to 10 ring members; R3 is a substituent selected from halogen, CN, N-linked monocyclic nitrogen-containing heterocyclic groups having from 3 to 7 ring members and containing up to three heteroatoms; and a group Ra-Rb. The substituents R4-R, Ra and Rb are defined in claim 1. The compounds have activity as inhibitors of cyclin dependent kinases and are useful in the treatment of disease states and conditions, such as proliferative diseases, mediated by cyclin dependent kinases.
• [EN] 2-AMINOPYRAZINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2004004730A3

  公开（公告）日：2004-04-29